ReNeuron Group plc Director Share Purchase (2499W)

TIDMRENE

RNS Number : 2499W

ReNeuron Group plc

07 February 2017

 
 7 February 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Director Share Purchase

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt, the Company's Chief Financial Officer, acquired 250,000 ordinary shares of 1p each ("Ordinary Shares") at a price of 2.64p per share.

Following this share purchase, Michael Hunt's total beneficial interest in the Company is 2,008,471 Ordinary Shares, representing 0.063 per cent of the Company's total voting rights.

ENQUIRIES:

 
ReNeuron                                                            [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            [phone] 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                      [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to purchase of Ordinary Shares)

 
  1   Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      Michael Hunt 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Chief Financial Officer 
---  ------------------------  ---------------------------------- 
 b)   Initial notification      Initial notification 
       /Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, 
       auctioneer or auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      ReNeuron Group plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       N/A 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) 
       each date; and (iv) each place where 
       transactions have been conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary Shares 0.01p 
       the financial 
       instrument, type          RENE - GB00B0DZML60 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Purchase of ordinary shares 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and                Price(s)   Volume(s) 
       volume(s)                  ---------  ---------- 
                                   2.64p      250,000 
                                  ---------  ---------- 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   7 February 2017 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM Market 
       transaction 
---  ------------------------  ---------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUBOURBAAURAR

(END) Dow Jones Newswires

February 07, 2017 07:32 ET (12:32 GMT)